Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
AZRX AzurRx BioPharma, Inc. daily Stock Chart
AZRX [NASD]
AzurRx BioPharma, Inc.
Healthcare | Biotechnology | USA
financial highlights | statements
Index- P/E- EPS (ttm)-0.88 Insider Own5.40% Shs Outstand16.87M Perf Week5.14%
Market Cap37.96M Forward P/E- EPS next Y-0.60 Insider Trans29.43% Shs Float10.86M Perf Month5.14%
Income-12.00M PEG- EPS next Q-0.18 Inst Own16.30% Short Float1.61% Perf Quarter56.26%
Sales- P/S- EPS this Y53.50% Inst Trans-14.12% Short Ratio1.68 Perf Half Y-9.63%
Book/sh0.33 P/B6.82 EPS next Y26.80% ROA-154.50% Target Price7.88 Perf Year-32.43%
Cash/sh0.26 P/C8.63 EPS next 5Y- ROE-301.40% 52W Range1.00 - 3.75 Perf YTD85.96%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-40.00% Beta-
Dividend %- Quick Ratio3.90 Sales past 5Y- Gross Margin- 52W Low125.01% ATR0.17
Employees12 Current Ratio3.90 Sales Q/Q- Oper. Margin- RSI (14)59.08 Volatility7.39% 7.13%
OptionableNo Debt/Eq0.00 EPS Q/Q45.40% Profit Margin- Rel Volume0.32 Prev Close2.27
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume103.80K Price2.25
Recom1.80 SMA209.96% SMA507.12% SMA200-4.43% Volume33,652 Change-0.88%
Oct-17-18Initiated Oppenheimer Outperform $6
Jul-24-17Initiated H.C. Wainwright Buy $8
Mar-18-19 07:45AM  AzurRx BioPharma Announces Presentation on Its Positive Phase II Data in MS1819-SD in Chronic Pancreatitis at the 2019 Digestive Disease Week Conference GlobeNewswire
Mar-15-19 07:45AM  AzurRx BioPharma to Present at the 2019 Annual Roth Capital Conference (March 19) and the Oppenheimer 29th Annual Healthcare Conference (March 20) GlobeNewswire +7.37%
Mar-12-19 07:45AM  AzurRx BioPharma Announces Poster Presentation at the Americas Hepato-Pancreato-Biliary Association 2019 Annual Meeting GlobeNewswire
Feb-20-19 07:45AM  AzurRx BioPharma Announces First Patients Dosed in Phase II OPTION Clinical Trial GlobeNewswire +18.24%
Jan-21-19 11:52AM  What Kind Of Shareholder Owns Most AzurRx BioPharma, Inc. (NASDAQ:AZRX) Stock? Simply Wall St.
Dec-19-18 08:00AM  AzurRx BioPharma Announces Initiation of Phase II OPTION Clinical Trial of MS1819-SD in Cystic Fibrosis Patients GlobeNewswire
Dec-12-18 08:00AM  AzurRx BioPharma to Acquire Payment Rights to Lead Drug Candidate MS1819-SD from Protea Biosciences Group GlobeNewswire
Dec-04-18 09:45AM  AZRX: 3Q:18 Financial and Operational Summary Zacks Small Cap Research
08:00AM  AzurRx BioPharma to Present at Upcoming Investor Conferences GlobeNewswire
Nov-01-18 07:30AM  AzurRx BioPharma Receives Sanction of Cystic Fibrosis Therapeutics Development Network for the Study of MS1819-SD in CF Patients with EPI GlobeNewswire +8.60%
Oct-16-18 07:30AM  AzurRx BioPharma Announces FDA Acceptance of IND Application for Phase 2 Clinical Trial of MS1819-SD in Patients with Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis GlobeNewswire
Sep-24-18 03:45PM  AZRX: Final Results from Phase II EPI Trial Zacks Small Cap Research +11.32%
07:45AM  AzurRx BioPharma Announces Positive Outcome with MS1819-SD Showing Statistically Significant Efficacy in a Phase IIa Exocrine Pancreatic Insufficiency Trial in Chronic Pancreatitis GlobeNewswire
Aug-28-18 09:45AM  AZRX: Phase 2 Cystic Fibrosis Study to Start Zacks Small Cap Research
08:30AM  AzurRx BioPharma to Present at the Rodman & Renshaw 20th Annual Global Investment Conference on September 5th GlobeNewswire
Aug-01-18 08:30AM  AzurRx BioPharma to Present at the 2018 Cannacord Genuity 38th Annual Growth Conference (August 9th) GlobeNewswire -6.27%
Jul-02-18 09:30AM  AZRX: AzurRx Announces Completion of Phase 2a MS1819 Trial Zacks Small Cap Research
Jun-29-18 08:30AM  AzurRx BioPharma Announces Successful Phase IIa Trial of MS1819-SD in Exocrine Pancreatic Insufficiency GlobeNewswire +5.59%
May-30-18 08:03AM  AzurRx Announces Appointment of Dr. James Pennington as Chief Medical Officer GlobeNewswire
May-02-18 11:15AM  AZRX: AzurRx Raises Capital After Confirming Results Zacks Small Cap Research +8.05%
May-01-18 09:10AM  AzurRx BioPharma Announces Pricing of $10.4 Million Public Offering of Common Stock GlobeNewswire -7.74%
07:51AM  Benzinga's Daily Biotech Pulse: Karyopharm's STORM Study, Inogen Rallies On Earnings Benzinga
Apr-30-18 04:15PM  AzurRx BioPharma Announces Proposed Public Offering of Common Stock GlobeNewswire
Apr-23-18 08:45AM  AzurRx BioPharma and Mayoly-Spindler Announce Additional Positive Interim Data for MS1819-SD Phase II in Exocrine Pancreatic Insufficiency (EPI) GlobeNewswire -11.92%
Apr-18-18 07:45AM  AzurRx BioPharma Announces Positive Preclinical Data with AZX1103 GlobeNewswire
Apr-13-18 01:15PM  AZRX: French Sites to Help Achieve 1H:18 Enrollment Goal Zacks Small Cap Research +10.86%
Mar-02-18 09:00AM  Stock Market Manager Announces the Hosting of Research Coverage of AzurRx, Biopharma, Inc. (NASDAQ: AZRX) by Trickle Research LLC ACCESSWIRE
Feb-28-18 08:30AM  AzurRx BioPharma to Present at the 30th Annual ROTH Conference (March 12th) GlobeNewswire -5.80%
Feb-12-18 08:15AM  AzurRx BioPharma Announces Enrollment of Three New Patients for its Phase IIa Study of MS1819-SD GlobeNewswire
Feb-08-18 04:30PM  AzurRx BioPharma to Present at the 2018 BIO CEO & Investor Conference (February 12th) GlobeNewswire
Jan-30-18 09:00AM  SeeThruEquity Initiates Coverage on AzurRx BioPharma, Inc. (NASDAQ CM: AZRX) with a Price Target of $10.00 ACCESSWIRE +13.73%
Jan-18-18 08:00AM  AzurRx BioPharma Announces Receipt of Required Approvals to Add French Clinical Site for its Phase IIa Study of MS1819-SD for Exocrine Pancreatic Insufficiency GlobeNewswire
Jan-16-18 11:16PM  AzurRx BioPharma Receives $2 Million in Proceeds from Exercise of Warrants GlobeNewswire
Dec-20-17 07:30AM  AzurRx BioPharma Announces Publication of U.S. Patent Application for AZX1101 GlobeNewswire
Dec-04-17 07:00AM  AzurRx BioPharma to Present at the Biotech Showcase 2018 Conference (January 8th) GlobeNewswire
Dec-01-17 05:50PM  Why AzurRx BioPharma Incs (AZRX) Investor Composition Impacts Your Returns Simply Wall St.
07:30AM  AzurRx BioPharma to Present at the 2017 LD Micro 10th Annual Main Event Conference (December 5th) GlobeNewswire
Oct-20-17 08:30AM  AzurRx BioPharma and Mayoly Spindler Announce MS1819-SD Investigational Medicinal Product Dossier (IMPD) Submission GlobeNewswire
Oct-16-17 08:30AM  AzurRx Announces Addition of Dr. Vern Lee Schramm to the Board of Directors GlobeNewswire -5.88%
Oct-11-17 03:54PM  Healthcare Industry Trends And Its Impact On AzurRx BioPharma Inc (AZRX) Simply Wall St.
Sep-27-17 09:00AM  AZRX: Update on MS1819 Phase II Trial Zacks Small Cap Research
08:30AM  AzurRx BioPharma and Mayoly-Spindler Announce Positive MS1819-SD Phase II Data in Exocrine Pancreatic Insufficiency (EPI) GlobeNewswire
Sep-25-17 08:30AM  AzurRx Announces Appointment of Maged Shenouda as Chief Financial Officer GlobeNewswire
Sep-05-17 08:30AM  MicroCap Review Magazine Fall 2017 Issue Now Available ACCESSWIRE +5.74%
Aug-28-17 01:00PM  AZRX: Fall Data Announcement for MS 1819 Zacks Small Cap Research -5.90%
Aug-24-17 08:00AM  AzurRx BioPharma to Present at the Rodman & Renshaw 19th Annual Global Investment Conference on September 12 GlobeNewswire +7.50%
Aug-23-17 08:00AM  AzurRx Reaches 6th Patient Enrollment of Phase IIa Trial of MS1819 for Treatment of Exocrine Pancreatic Insufficiency Associated with Chronic Pancreatitis GlobeNewswire
Jun-08-17 08:00AM  AzurRx BioPharma Announces Closing of $5.0 Million Private Financing GlobeNewswire +11.60%
Jun-05-17 04:30PM  AzurRx BioPharma to Present at the 2017 LD Micro Invitational Conference (June 6) and the 2017 Marcum MicroCap Conference (June 15) GlobeNewswire
Apr-17-17 02:00PM  AZRX: MS 1819 Trial, First Look Positive; 2016 Results Zacks Small Cap Research +9.92%
Apr-11-17 08:00AM  AzurRx Provides Update on MS1819 Phase II Trial GlobeNewswire
Mar-08-17 09:33AM  AzurRx Announces Addition of Charles J Casamento to the Board of Directors GlobeNewswire
Mar-01-17 11:18AM  LifeSci Capital Initiates Coverage of AzurRx BioPharma Accesswire
Jan-25-17 10:00AM  AZRX: Non-systemic Focus on the GI Market Zacks Small Cap Research
Jan-05-17 03:09PM  Is AzurRx About to Transform the Gastrointestinal Treatment Industry? GuruFocus.com
Dec-28-16 08:00AM  AzurRx BioPharma to Present at the 2017 Biotech Showcase Conference GlobeNewswire
Dec-27-16 03:54PM  An Emerging Leader to Treat Gastrointestinal Disease GuruFocus.com
Dec-21-16 08:00AM  AzurRx BioPharma Announces First Three Patients Included in Phase IIa Study with MS1819-SD for Endocrine Pancreatic Insufficiency GlobeNewswire
Dec-12-16 08:00AM  WallachBeth Capital Initiates Research Coverage of AzurRx BioPharma GlobeNewswire
Dec-06-16 08:00AM  AzurRx BioPharma Announces Agreement in Principle with TransChem for MTAN Inhibition Technology GlobeNewswire
05:59AM  Coverage initiated on AzurRx BioPharma by WallachBeth
Dec-01-16 08:00AM  AzurRx CEO Provides Shareholders With a "State of the Union" Communication GlobeNewswire
Nov-30-16 05:17PM  AzurRx BioPharma to Present at the 9th Annual LD Micro Main Event Accesswire
Oct-16-16 09:15AM  IPO Market Could Launch 4 New Firms Next Week 24/7 Wall St.
Oct-12-16 11:42AM  Heres Why AzurRx BioPharma, Lions Gate Entertainment, Barracuda Networks and Two Other Stocks Are on the Move Today Insider Monkey
AzurRx BioPharma, Inc. researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea. The company was incorporated in 2014 and is headquartered in Brooklyn, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ross Edmund Burke Jr.10% OwnerDec 31Buy1.1223,84826,7102,540,555Jan 07 06:49 PM
Spoor Johan M.PRESIDENT AND CEODec 28Buy1.3038,58349,969338,617Jan 02 06:47 PM
Shenouda MagedCHIEF FINANCIAL OFFICERDec 28Buy1.3120,00026,21462,500Jan 02 06:44 PM
CASAMENTO CHARLES JDirectorDec 28Buy1.419,00012,69056,500Jan 02 05:58 PM
Ross Edmund Burke Jr.10% OwnerDec 28Buy1.1829,57534,8992,516,707Jan 07 06:49 PM
Ross Edmund Burke Jr.10% OwnerDec 27Buy1.1666,12276,8642,487,132Jan 07 06:49 PM
Ross Edmund Burke Jr.10% OwnerMay 02Buy2.5020,00050,0002,421,010Jan 07 06:49 PM
open in yahoo | open in reuters | open in google